Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOAnab1: Nab-paclitaxel + Gemcitabine Mechanism of Action in Pancreatic Cancer
NCT02174887Phase 1Completed
- Sponsor
- Institut Paoli-Calmettes
- Start
- Sep 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Institut Paoli-Calmettes. Primary endpoint: Vascularization parameters of pancreatic carcinoma at 2 months. Started Sep 2014; status: completed.
02
Drugs
paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02174887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02174887.